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Prediction of Mortality After Primary Percutaneous
oronary Intervention for Acute Myocardial Infarction
he CADILLAC Risk Score
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illiam W. O’Neill, MD, FACC,‡ Roxana Mehran, MD, FACC,* Gregg W. Stone, MD, FACC*
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OBJECTIVES We sought to develop a simple risk score for predicting mortality after primary percutaneous
coronary intervention (PCI) for acute myocardial infarction (AMI).
BACKGROUND Accurate risk stratification after primary PCI is important. Previous risk scores after
reperfusion therapy have incorporated clinical  angiographic variables but have not
considered baseline left ventricular function. Moreover, prior studies have not been validated
against independent databases or studies.
METHODS The databases from the two largest multicenter, randomized AMI trials of primary PCI were
utilized for score derivation (the Controlled Abciximab and Device Investigation to Lower
Late Angioplasty Complications [CADILLAC] trial, n  2,082) and subsequent validation
(the Stent-Primary Angioplasty in Myocardial Infarction [Stent-PAMI] trial, n  900).
Logistic regression and the jackknife procedure were used to select correlates of one-year
mortality that were subsequently weighted and integrated into an integer scoring system.
RESULTS Seven variables selected from the initial multivariate model were weighted proportionally to
their respective odds ratio for one-year mortality (age 65 years [2 points], Killip class 2/3
[3 points], baseline left ventricular ejection fraction40% [4 points], anemia [2 points], renal
insufficiency [3 points], triple-vessel disease [2 points], and post-procedural Thrombolysis In
Myocardial Infarction flow grade [2 points]). Three strata of risk were defined (low risk, score
0 to 2; intermediate risk, score 3 to 5; and high risk, score 6) with excellent prognostic
accuracy for survival in the derivation and validation sets (c statistics  0.83 and 0.81 for
30-day mortality and 0.79 and 0.78 for 1-year mortality, respectively).
CONCLUSIONS In AMI patients treated with primary PCI, seven risk factors readily available at the time of
intervention accurately predict short- and long-term mortality. Of note, measurement of
baseline left ventricular function is the single most powerful predictor of survival and should
be incorporated into risk score models. (J Am Coll Cardiol 2005;45:1397–405) © 2005 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.041the American College of Cardiology Foundation
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the evolution and widespread adoption of primary percu-
aneous coronary intervention (PCI) represents a major
dvance in the management of acute myocardial infarction
AMI), resulting in a significant reduction in early and late
ortality compared with pharmacologic reperfusion therapy
1). Nonetheless, considerable variability in survival rate
fter primary PCI is present and accurate risk stratification
s therefore of clinical importance. Several risk scores using
emographic and electrocardiographic variables have been
eveloped from thrombolysis trials (2–5), but their applica-
ility to the primary PCI setting is unknown. Moreover,
atheter-based reperfusion offers the additional opportunity
From *Columbia University Medical Center and the Cardiovascular Research
oundation, New York, New York; †Mayo Clinic and Foundation, Rochester,
innesota; ‡William Beaumont Hospital, Royal Oak, Michigan; §Duke Clinical
esearch Institute, Durham, North Carolina; Hospital Gregorio Maranon, Madrid,
pain; ¶Mid Carolina Cardiology, Charlotte, North Carolina; #Washington Ad-
entist Hospital, Tacoma Park, Maryland; and **Moses Cone Hospital, Greensboro,
orth Carolina.(
Manuscript received October 25, 2004; revised manuscript received January 19,
005, accepted January 19, 2005.o include angiographic and left ventricular function data in
he risk models, which are known to be of prognostic utility
6,7). Risk scores developed from populations treated exclu-
ively by primary PCI, however, have either not incorpo-
ated any angiographic variables (8) or have excluded left
entricular ejection fraction (LVEF) (9), one of the most
owerful prognostic determinates. Finally, validation
gainst independent study populations is the most rigorous
est of a risk score (10). A comprehensive clinical and
ngiographic primary angioplasty risk model subjected to
trict validation has not been reported.
We therefore sought to derive a simple clinical scoring
ystem for prediction of short- and long-term mortality after
rimary PCI utilizing clinical, procedural, and angiographic
nformation available at the time of intervention (including
eft ventricular function) and to validate this risk score
gainst an independent study cohort. To this end, the
atabases from the two largest multicenter, randomized AMI
rials of primary PCI to date were utilized for score derivation
the Controlled Abciximab and Device Investigation to Lower
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Risk Score for Primary Angioplasty May 3, 2005:1397–405ate Angioplasty Complications [CADILLAC] trial [11],
 2,082] and subsequent validation (the Stent-Primary
ngioplasty in Myocardial Infarction [Stent-PAMI] trial
12], n  900).
ETHODS
he risk score was derived from the CADILLAC trial
atabase, which comprises the largest and most comprehen-
ive primary PCI database to date. In the CADILLAC
rial, 2,082 patients of any age with AMI and symptoms
asting 30 min but 12 h who were not in cardiogenic
hock at the time of presentation were enrolled (11).
dditional major exclusion criteria included failed throm-
olytic therapy (rescue PCI), the requirement for multives-
el PCI during the index procedure, bleeding diatheses,
erebrovascular accident within the preceding two years,
nown hepatic or renal dysfunction, and the presence of
erious co-morbidities with a life expectancy of less than one
ear. Angiographic inclusion criteria required a culprit
rtery with a reference diameter of 2.5 to 4.0 mm and lesion
ength 64 mm. After coronary arteriography and left
entriculography, patients were assigned randomly to either
alloon angioplasty or stenting, each  abciximab. Detailed
linical follow-up was obtained during hospitalization and
t discharge, one month, six months, and one year.
For the validation set, the database from the Stent-PAMI
rial was utilized, in which 900 eligible patients undergoing
rimary PCI were assigned randomly to stenting versus
alloon angioplasty. The clinical and angiographic entry
riteria, medications used, and procedural performance were
imilar between the Stent-PAMI and CADILLAC trials,
xcept that abciximab was used in only5% of patients in the
tent-PAMI trial compared to 53% in the CADILLAC
rial, and the use of the MultiLink stent (Guidant, Santa
lara, California) in the CADILLAC trial compared with
he heparin-coated Palmaz-Schatz stent in the Stent-PAMI
rial afforded treatment of smaller vessels and longer lesions
n the CADILLAC trial (12). The 30-day and 1-year
ortality rates, however, were similar between the two
Abbreviations and Acronyms
AMI  acute myocardial infarction
CADILLAC  Controlled Abciximab and Device
Investigation to Lower Late Angioplasty
Complications trial
CI  confidence interval
LVEF  left ventricular ejection fraction
OR  odds ratio
PCI  percutaneous coronary intervention
ROC  receiver-operating characteristic
Stent-PAMI  Stent-Primary Angioplasty in Myocardial
Infarction trialtudies. 1uantitative coronary angiography and left ventriculo-
raphy. Quantitative coronary angiography and left ven-
riculography were performed at the same independent core
ngiographic laboratory (the Cardiovascular Research
oundation, New York, New York) for both studies. An-
egrade blood flow in the infarct artery was graded using the
hrombolysis In Myocardial Infarction (TIMI) scale (13).
VEF was calculated by the area-length method (14), and
egional wall motion was determined by the centerline
hord method (15).
nd points and statistical analysis. Categorical data were
ompared using the chi-square test. Continuous variables
re presented as medians and interquartile ranges and were
ompared using the nonparametric Kruskal-Wallis test.
linical outcomes are presented as Kaplan-Meier survival
ercentages and were compared using the log-rank test. For
ll analyses a two-sided p 0.05 was considered statistically
ignificant.
Baseline demographic, clinical, and angiographic param-
ters in the CADILLAC database were examined by
nivariate logistic regression analysis for their relation to
ne-year all-cause mortality, the primary end point for the
urrent risk score. All variables in Table 1 were available for
election in this model. Left ventricular ejection fraction,
ematocrit level, creatinine clearance, and age were dichot-
mized and treated as binary variables, based on previous
ork (6,16–18). Severe left ventricular systolic dysfunction
as defined as an LVEF0.40 (6). Based on World Health
rganization criteria, anemia was defined as a baseline
ematocrit level 39% for men and 36% for women (19).
reatinine clearance was calculated by the Cockcroft-Gault
ormula corrected for gender (20), and baseline renal insuf-
ciency was defined as a creatinine clearance 60 ml/min
21). Significant univariate predictors of one-year mortality
ere subjected to a forward stepwise selection process (entry
nd exit criteria p  0.05 and p  0.10, respectively) in a
equence of “leave one out” jackknife procedures (n  2,082).
or variables selected in 85% of the samples, the odds
atio of one-year mortality rate was calculated in a final
ultivariate logistic regression analysis. Each of these vari-
bles was assigned a weighted score proportional to the
ultivariate odds ratio for one-year mortality. For the final
core, three risk strata (low, intermediate, and high risk)
ere defined based on event rates for each individual score
ithin the entire range resulting from the various combi-
ations of weighted risk predictors. Event rates for each of
hese risk classes were calculated for the CADILLAC
ataset and subsequently validated in the Stent-PAMI
atabase. The discriminatory capacity of the model was
ssessed using the area under the receiver-operating char-
cteristic (ROC) curve, and the difference between model-
redicted and observed event rates (goodness-of-fit) was
valuated with the Hosmer-Lemeshow test (22) [p  0.10
onsidered to indicate lack of deviation between the model
nd observed event rates (23)]. The prognostic utility of this
-year risk score was also evaluated for all-cause mortality at 30
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May 3, 2005:1397–405 Risk Score for Primary Angioplastyays. The areas under the ROC curves of the CADILLAC
core and previous predictive models were compared using the
onparametric method of Delong et al. (24).
ESULTS
nivariate and multivariate predictors of one-year mor-
ality. Baseline characteristics and adverse event rates in
he derivation and validation sets are shown in Tables 1
nd 2, respectively. At one-year follow-up, 89 (4.3%) and
8 (4.3%) patients had died in the CADILLAC and
tent-PAMI trials, respectively. Statistically significant uni-
ariate predictors of one-year mortality in the CADILLAC
rial are listed in Table 3. Of note, neither randomization to
bciximab (odds ratio [OR] 0.96, 95% confidence interval
CI] 0.63 to 1.46], p  0.83) nor stenting (OR 1.03, 95%
I 0.63 to 1.46, p  0.88) were univariate correlates of
Table 1. Baseline Characteristics and Procedur
Clinical features
Age (yrs)
Male gender (%)
Diabetes mellitus (%)
Current smoker (%)
Hypercholesterolemia (%)
Hypertension (%)
Previous myocardial infarction (%)
Previous coronary angioplasty (%)
Previous bypass surgery (%)
History of cerebrovascular disease (%)
History of peripheral vascular disease (%)
Body mass index (kg/m2)
Killip class 2/3 (%)
Sustained hypotension on admission* (%)
Symptom onset to balloon inflation (h)
Creatinine clearance (ml/min)
Creatinine clearance 60 ml/min (%)
Hematocrit (%)
Anemia (%)
Angiographic features
Three vessel disease (%)
Infarct vessel  left anterior descending (%)
Reference vessel diameter (mm)
Minimal luminal diameter, pre (mm)
Diameter stenosis, pre (%)
TIMI flow grade 3, pre (%)
Baseline LVEF (%)
Baseline LVEF 0.40 (%)
Procedural features and outcomes
Stent implanted (%) 5
Abciximab administered (%)
Maximal balloon diameter (mm)
Maximal inflation pressure (atm)
Minimal luminal diameter, post (mm)
Diameter stenosis, post (%)
TIMI flow grade 3, post (%)
*Defined in CADILLAC as systolic blood pressure90 mm
as systolic blood pressure 80 mm Hg for 60 min, requir
LVEF  left ventricular ejection fraction; N/A  not availne-year mortality. Similarly, neither the time from iymptom onset to reperfusion (OR 1.02, 95% CI 0.96 to
.09, p  0.53) nor door to balloon time (OR 1.05, 95%
I 0.97, 1.14, p  0.21) significantly predicted one-year
ortality.
Seven predictors were selected in at least 85% of the
ackknife samples by multivariate analysis as independent
redictors of one-year mortality (Table 3). Using these
ariables, the area under the ROC curve was 0.81 with a
osmer-Lemeshow p value of 0.22, indicating good dis-
riminatory power and goodness-of-fit. When applied to
he 30-day mortality end point, the area under the ROC
urve for this model was 0.89 with a Hosmer-Lemeshow p
alue of 0.36. Of note, a simpler model was considered with
nly six variables, excluding post-PCI TIMI flow grades 0
o 2, for which the multivariate p value was 0.06. However,
nclusion of post-procedural TIMI flow grades 0 to 2 flow
sults in the Derivation and Validation Sets
DILLAC
ivation Set
 2,082)
Stent-PAMI
Validation Set
(n  900) p Value
(51.0, 69.0) 60.1 (50.6, 69.6) 0.39
73.0 74.8 0.32
16.6 15.1 0.33
43.1 46.7 0.08
37.9 42.0 0.05
48.1 42.1 0.003
13.7 11.3 0.09
11.2 8.2 0.02
1.9 1.5 0.46
3.0 3.8 0.31
2.7 4.0 0.08
(24.8, 30.4) N/A N/A
10.9 6.9 0.0009
1.5 3.1 0.24
(2.88, 6.10) 3.96 (2.92, 5.68) 0.27
(66.1, 111.5) 85.4 (65.2, 108.3) 0.11
18.1 19.6 0.40
(40, 45) 42.7 (39.5, 45.4) 0.13
12.0 14.4 0.08
15.6 13.8 0.22
36.7 41.7 0.01
(2.61, 3.33) 2.88 (2.62, 3.27) 0.24
(0.00, 0.72) 0.00 (0.00, 0.86) 0.32
(75, 100) 100 (70, 100) 0.26
22.1 21.4 0.70
(47.3, 63.4) 55.7 (46.0, 61.9) 0.12
20.5 20.5 0.99
,182/2,082) 56.4 (508/900) 0.87
53.1 5.1 0.0001
(3.00, 3.50) 3.50 (3.00, 3.50) 0.04
(9, 15) 12 (8, 16) 0.34
(1.94, 2.60) 2.30 (2.02, 2.68) 0.001
(16.9, 31.3) 23.0 (17.0, 30.7) 0.94
95.6 91.1 0.0001
30 min, or requiring vasopressors; defined in Stent-PAMI
opressors or an intraaortic balloon pump.
applicable; TIMI  Thrombolysis In Myocardial Infarction.al Re
CA
Der
(n
59.0
27.2
3.97
88.2
43.0
2.95
0.00
100
60.0
6.8 (1
3.50
12
2.25
23.1
Hg forn the one-year model resulted in a reduction of the 2 log
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Risk Score for Primary Angioplasty May 3, 2005:1397–405ikelihood statistic from 491.58 to 486.49 (p  0.024),
ndicating that the presence of this variable in the final risk
core improved the adequacy of the model, and thus it was
etained.
erivation and validation of the CADILLAC trial risk
core: mortality prediction. The observed rates of one-year
ortality according to this scoring system are shown in Figure
. After identifying the one-year mortality rate and the number
f patients for individual scores, a risk score was developed
ased on the sum of weighted predictors present in each case.
Table 2. Adverse Event Rates in the Derivatio
In-hospital adverse event rates
Death (%)
Reinfarction (%)
Disabling stroke (%)
Ischemic target vessel revascularization (%)
30-day adverse event rates
Death (%)
Reinfarction (%)
Disabling stroke (%)
Ischemic target vessel revascularization (%)
1-year adverse event rates
Death (%)
Reinfarction (%)
Disabling stroke (%)
Ischemic target vessel revascularization (%)
Table 3. Clinical and Angiographic Predictors
Odd
Univariate predictors
Renal insufficiency 5
In-hospital stroke 5
Baseline LVEF 40% 4
Age 65 yrs 4
Sustained hypotension on admission 4
Killip class 2/3 4
Anemia 3
Female gender 2
Final TIMI flow grades 0 to 2 2
Infarct artery  left anterior descending 2
Three vessel disease 2
Diabetes 1
Hypertension 1
Body mass index 0
Reference vessel diameter 0
Final minimal luminal diameter 0
Smoker 0
Multivariable predictors*
Baseline LVEF 40% 3
Renal insufficiency 2
Killip class 2/3 2
Final TIMI flow grades 0 to 2 2
Age 65 yrs 2
Anemia 2
Three vessel disease 2*Selected in at least 85% of the multivariable analyses in the jackk
CI  confidence interval; other abbreviations as in Table 1.or simplicity, three risk strata were defined (low risk, score 0
o 2, encompassing 56.5% of the patients in the CADILLAC
rial; intermediate risk, score 3 to 5, 23.8% of patients; and high
isk, score 6, 19.7% of patients). The predictive accuracy of
his scoring system for one-year mortality was as precise when
pplied to the Stent-PAMI trial validation dataset as for the
ADILLAC trial derivation dataset (Fig. 2A). Moreover, the
redictive accuracy of the risk score was retained when applied
o the 30-day all-cause mortality end point in both the
ADILLAC and Stent-PAMI trial datasets (Fig. 2B). Sur-
Validation Sets
DILLAC
ivation Set
 2,082)
Stent-PAMI
Validation Set
(n  900) p Value
1.6 2.4 0.14
0.2 0.4 0.46
0.0 0.1 0.51
0.0 0.1 0.13
2.1 2.7 0.36
0.8 0.8 0.91
0.1 0.2 0.63
3.4 2.5 0.13
4.3 4.3 0.99
2.4 2.9 0.49
0.6 0.5 0.74
13.3 16.0 0.10
ne-Year Mortality in the CADILLAC Trial
io 95% CI p Value
Integer Score
Assigned†
3.83–9.40 0.0001 —
1.19–27.26 0.03 —
2.96–7.40 0.0001 —
2.90–7.19 0.0001 —
1.69–12.02 0.003 —
2.75–7.01 0.0001 —
1.97–5.19 0.0001 —
1.82–4.27 0.0001 —
1.25–5.33 0.01 —
1.49–3.52 0.0002 —
1.37–3.57 0.001 —
1.17–3.28 0.01 —
1.05–2.50 0.03 —
0.84–0.94 0.0001 —
0.42–0.94 0.02 —
0.41–0.90 0.01 —
0.31–0.80 0.004 —
2.07–5.75 0.0001 4
1.52–4.92 0.0008 3
1.42–4.67 0.002 3
0.97–5.54 0.06 2
1.23–4.10 0.008 2
1.24–4.05 0.007 2
1.18–3.63 0.01 2n and
CA
Der
(nof O
s Rat
.99
.70
.67
.57
.50
.39
.19
.78
.58
.29
.21
.95
.62
.89
.62
.61
.50
.50
.73
.57
.31
.25
.24
.07nife model. †Approximating the odds ratio.
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May 3, 2005:1397–405 Risk Score for Primary Angioplastyival at various time points between 30 days and 1 year among
ADILLAC patients stratified by risk class is shown in Figure
, showing prognostic utility at all times throughout the
ollow-up period.
omparison with previous score systems. To compare
he performance of the CADILLAC trial score with that of
reviously reported models for mortality prediction after reper-
usion therapy, we applied the recent TIMI ST-segment
levation (4), PAMI (8), and Zwolle (9) risk models to the
alidation set of the current study. As shown in Table 4, the
ADILLAC trial score compared favorably with these
revious risk models in prognostic performance and fitting
f the data. The CADILLAC trial score was more accurate
n terms of predicting 30-day mortality (p  0.02) and
-year mortality (p  0.06).
igure 1. Integer scoring system and corresponding one-year mortality
yocardial Infarction.igure 2. Score-based risk classification system with corresponding 1-year (A
ADILLAC (solid bars) and Stent-PAMI (open bars) trial datasets.ISCUSSION
he principal findings of the current study, in which a
ew powerful cardiac risk score was created and validated,
re 1) after primary PCI in AMI, 30-day and 1-year
ortality can be accurately predicted using seven clinical
nd angiographic variables readily available at the time of
ntervention; 2) baseline LVEF is the single most pow-
rful predictive variable of mortality and should be
ncorporated into risk models; 3) using this prognostic
core, three levels of risk strata can be created that
dentify patients with AMI undergoing primary PCI in
hom one-year mortality is extraordinarily low (1%),
ntermediate (4% to 5%), and high (12%); 4) the
urrent risk score, when validated against an independent
LVEF  left ventricular ejection fraction; TIMI  Thrombolysis Inrates.) and 30-day (B) mortality rates and discriminatory performance in the
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Risk Score for Primary Angioplasty May 3, 2005:1397–405andomized trial study dataset, provided more discrimi-
atory power and goodness of fit for one-year mortality
han prior risk models that did not incorporate a full
ange of baseline angiographic variables.
utcome prediction after primary PCI. Accurate risk
tratification after primary PCI is of importance in guiding
atient management, resource utilization, and the design of
linical trials. Previous work has shown that the predictive
apability of a risk model largely depends on the populations
n which it was developed and to which it is applied (25).
ost prior scores for mortality prediction after reperfusion
herapy have been derived from thrombolytic therapy trials
2–5), whereas recent primary PCI risk models have differed
rom the present CADILLAC trial score in the risk factors
ncluded (8,9). Moreover, a comprehensive clinical and
ngiographic primary angioplasty risk model, subjected to
trict validation against an independent study population,
as not been reported.
The CADILLAC trial score, derived and externally
alidated using separate databases from the two largest
ulticenter randomized trials of primary PCI to date, was
ound to have an excellent predictive capacity for both
0-day and 1-year mortality (c statistics  0.83 and 0.81 for
0-day mortality and 0.79 and 0.78 for 1-year mortality,
espectively, for the CADILLAC trial derivation set and
he Stent-PAMI trial validation set). Moreover, this risk
core allowed the creation of risk strata in which 56% of
atients had mortality rate of 1% at 1-year (similar to that
xpected in an age-matched controlled population), an
ntermediate risk population in which24% of patients had
Figure 3. Freedom from all-cause mortality among-fold higher 1-year mortality (of 4.0% to 4.5%), and a tigh risk subgroup comprising 20% of patients with a
5-fold higher 1-year mortality (12%). Thus, despite the
act that both trials excluded patients with cardiogenic
hock, use of the risk score enables identification of a sizable
ohort with a very poor long-term prognosis in whom close
onitoring and aggressive therapy may be beneficial.
redictors of mortality in the CADILLAC trial score
nd previous models. Angiographic findings such as
VEF and the severity of coronary artery disease are of
ocumented prognostic importance in AMI (7) and PCI
26) risk models. Models derived from thrombolytic therapy
rials in which early cardiac catheterization was not rou-
inely performed did not incorporate these variables into the
ormulation of risk scores, potentially limiting their power.
secondary advantage of primary PCI as a reperfusion
odality is the ability to readily assess measures of baseline
eft ventricular function and the extent of coronary artery
isease. However, recently reported PCI risk scores have
ither not utilized angiographic information (8) or have
xcluded LVEF (9) from the candidate variables.
The current analysis calls attention to the synergistic prog-
ostic impact of both clinical and angiographic variables as
ell as factors that are potentially modifiable or that mandate
pecific intervention. The baseline measure of LVEF was
dentified as the most powerful long-term determinate of
ortality and should thus be incorporated into risk models to
btain maximal predictive accuracy. Patients presenting with a
ow LVEF should be followed up closely for signs of incipient
hock that might not be apparent at presentation (27). Aggres-
ive medical management of patients with reduced left ven-
CADILLAC trial patients stratified by risk class.ricular function is warranted to prevent sudden cardiac death
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May 3, 2005:1397–405 Risk Score for Primary Angioplastynd development of congestive heart failure (28–31). Of note,
ome operators do not routinely perform left ventriculography
uring the primary PCI procedure, and thus may not capture
he full range of prognostic data available. Whether the
redictive information from assessment of left ventricular
unction estimated by other modalities (e.g., echocardiography)
r at a later time has the same prognostic utility as the LVEF
btained during baseline contrast ventriculography is unknown.
It is also worth considering intervention for other risk factors
hat were retained in the final multivariable model. Our
ndings regarding the impact of multivessel disease on survival
mphasize the need for randomized clinical trials to determine
hether acute multivessel intervention can improve prognosis
n these high-risk patients, an approach to date not routinely
ecommended (32). Killip class at presentation, invariably a
omponent of previous scores (2,4,8,9), remained an indepen-
ent predictor of reduced short- and long-term survival in the
urrent study apart from baseline LVEF and the extent of
oronary artery disease, emphasizing the importance of the
linical examination for signs of mild to moderate heart failure
ven when left ventricular function is preserved. Anemia and
enal insufficiency are recognized increasingly as conditions
trongly predictive of mortality after AMI (16,17). The incre-
ental prognostic value of these conditions was demonstrated
n the current analysis and validated in an external dataset.
nemia represents a potentially modifiable risk factor, and in
ne report red blood cell transfusion was found to be associated
ith improved survival after AMI (33), an observation that
arrants prospective investigation. Efforts are also warranted to
inimize the occurrence of contrast nephropathy by adequate
ydration and utilizing minimal amounts of low osmolar
ontrast (34), by consideration of n-acetylcysteine (35) and
ossibly alkalinization (36).
Of note, certain clinical and electrocardiographic predic-
ors (e.g., diabetes, admission heart rate and blood pressure,
lectrocardiographic anterior AMI location, and/or left bundle
ranch block) that have been consistently present in previous
cores that did not incorporate angiographic variables (2,4,5,8)
re conspicuously absent from the final CADILLAC trial
core. The prognostic impact of these clinical variables,
hich were significant correlates of survival by univariate
nalysis but not by multivariate analysis in this study, were
ikely contained within the stronger angiographic predictors
f mortality in the CADILLAC trial score (e.g., LVEF at
aseline, triple vessel disease). Supporting this contention is
he report by De Luca et al. (9) in which consideration of
ultivessel disease and post-procedural TIMI flow grade
xcluded clinical variables other than age and Killip class
rom a risk model for 30-day mortality.
tudy limitations. Patients presenting with cardiogenic
hock, with complex coronary anatomy (e.g., left main
isease or bifurcation disease, and saphenous vein graft
cclusion), and those undergoing rescue PCI after failed
hrombolytic therapy were excluded from the CADILLAC
rial; whether these factors would add additional incremen-tal prognostic information or result in exclusion of otherTa
b
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Risk Score for Primary Angioplasty May 3, 2005:1397–405ariables in the current score is unknown. Because the mortal-
ty rate in patients with cardiogenic shock remains very high
ven when aggressively managed by modern interventional
trategies (37,38), this entity should probably be considered
eparately in the context of risk stratification. Operator expe-
ience and center volume (39) were not considered in the
urrent analysis. Nonetheless, the current score was derived
nd validated using databases from large multicenter trials
using permissive inclusion criteria and with patients enrolled
rom 76 institutions in the CADILLAC trial and 62 insti-
utions in the Stent-PAMI trial) so that it is likely to be
idely applicable to a broad cross-section of patient care
acilities. Measures of microvascular perfusion [e.g., resolu-
ion of ST-segment elevation and myocardial blush (40)]
re absent from this as well as previous primary PCI risk
core models (8,9), and may further improve prognostica-
ion beyond post-procedural TIMI flow grade. Addition-
lly, the time from symptom onset to reperfusion was not an
ndependent predictor of mortality in the current study.
ecent data suggest that primary PCI within 3 h of
ymptom onset compared with longer intervals is associated
ith improved survival, but when the time to reperfusion
xceeds 3 h, as was the case for most patients in the current
nalysis, further delays in reperfusion have minimal incre-
ental effect on either early or late mortality (41). Thus,
inimizing delays to PCI is always desirable, especially in
atients presenting early after symptom onset. Finally, we
hose to categorize the current score into only three risk
lasses, which likely resulted in an underestimation of the
rue predictive power of our model. Nevertheless, the
redictive accuracy of the CADILLAC trial score compared
avorably with that of previous scores that used a larger
umber of risk classes.
onclusions and clinical implications. Seven clinical and
ngiographic parameters routinely collected and readily
vailable at baseline or procedural completion (age, Killip
lass, baseline anemia and renal insufficiency, triple vessel
isease, LVEF, post-procedural TIMI flow grade) accu-
ately predict 30-day and 1-year mortality rates after pri-
ary PCI when integrated in a simple risk scoring system.
ur findings indicate that in the setting of contemporary
atheter-based reperfusion therapy for AMI, the severity of
oronary artery disease and evaluation of baseline LVEF
mportantly enhance risk stratification in concert with base-
ine demographic and clinical profiling. Further studies are
arranted to determine whether novel pharmacologic,
evice-based, or surgical approaches can further improve the
rognosis of the patients at highest risk after primary PCI as
dentified by the CADILLAC risk score.
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